AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsTechnology, Industry, AgricultureInformation ScienceHealth Care
Lipoproteins, IDLLipoproteinsLipoproteins, VLDLLipoproteins, LDLLipLipoproteins, HDLApolipoproteins BLipoprotein LipaseApolipoproteinsCleft LipCholesterolTriglyceridesHyperlipoproteinemia Type IIILipoprotein(a)Cholesterol, VLDLApolipoproteins EReceptors, LDLCentrifugation, Density GradientHyperlipidemiasHyperlipoproteinemiasApolipoprotein B-100Lip NeoplasmsUltracentrifugationCholesterol EstersLipidsCholesterol, DietaryLip DiseasesCholesterol, LDLCholesterol, HDLHypertriglyceridemiaLipaseLiverKineticsApolipoprotein C-IIIReceptors, LipoproteinHyperlipoproteinemia Type IIArteriosclerosisHypercholesterolemiaLipoproteins, HDL3RabbitsCell FractionationElectrophoresis, Agar GelParticle SizeLipoproteins, HDL2Electrophoresis, Polyacrylamide GelBone DensityCleft PalateLow Density Lipoprotein Receptor-Related Protein-1ChylomicronsModels, BiologicalApolipoproteins AMolecular Sequence DataOxidation-ReductionApolipoproteins CCells, CulturedLipid MetabolismPopulation DensityApolipoprotein B-48Apolipoprotein A-IITime FactorsPhospholipidsAmino Acid SequenceIntermediate Filament ProteinsProtein BindingMicroscopy, ElectronCarrier ProteinsApolipoprotein C-IICholesterol Ester Transfer ProteinsPhosphatidylcholine-Sterol O-AcyltransferaseDietary FatsReceptors, ScavengerMutationAtherosclerosisScavenger Receptors, Class BBase SequenceMacrophagesCell LineApoprotein(a)Hyperlipoproteinemia Type IVRisk FactorsBiological TransportApoproteinsModels, MolecularHeparinFatty AcidsHyperlipoproteinemia Type IRNA, MessengerEscherichia coliTrioleinAnticholesteremic AgentsCattleMolecular WeightBinding SitesAntigens, CD36Cell MembraneHypolipidemic AgentsLipolysisPhenotypeFoam CellsProtein Conformation
CholesterolPhenotypesHighHigh-density lipoprotein choVLDLCardiovascularLevelsDevelopPatientsYear
Cholesterol7
Phenotypes4
  • Studies relating differential methylation with intermediate phenotypes and disease endpoints may be useful in identifying additional candidate genes and mechanisms involved in disease. (biomedcentral.com)
  • Thus, studies relating differential methylation with intermediate phenotypes and disease endpoints may be useful in identifying additional candidate genes and mechanisms involved in these diseases [ 22 ]. (biomedcentral.com)
  • GNPTAB-related disorders comprise the phenotypes mucolipidosis II (ML II) and mucolipidosis IIIa/ß (ML IIIa/ß), and phenotypes intermediate between ML II and ML IIIa/ß. (nih.gov)
  • Phenotypes intermediate between ML II and ML IIIa/ß are characterized by physical growth in infancy that resembles that of ML II and neuromotor and speech development that resemble that of ML IIIa/ß. (nih.gov)
High2
  • What does it mean if your Intermediate Density Lipoprotein (IDL-1) result is too high? (healthmatters.io)
  • Tangier disease is characterized by severe deficiency or absence of high-density lipoprotein (HDL) in the circulation resulting in tissue accumulation of cholesteryl esters throughout the body, particularly in the reticuloendothelial system. (nih.gov)
High-density lipoprotein cho3
  • Unlike arteriosclerosis in the general population, however, in progeria, the only lipid abnormality is decreased high-density lipoprotein cholesterol levels. (medscape.com)
  • After the intervention, the experimental group showed a significantly higher increase in high-density lipoprotein cholesterol level than did the control group (effect size=0.152, p=0.019). (e-arm.org)
  • In addition, plasma concentration of non-high-density lipoprotein cholesterol (non-HDL-C), very low-density lipoprotein (VLDL) cholesterol, and VLDL-TG remarkedly reduced after IPE (4 g/day) treatment by a median of 14.6%, 27.9%, and 25.2%, respectively compared with participants in placebo group. (bvsalud.org)
VLDL2
  • Lipoproteins are classified as very low-density (VLDL), low-density (LDL), intermediate-density (IDL), and high-density (HDL). (unboundmedicine.com)
  • Considering the relationship between the extent of metabolic derangement and the disease severity in heart failure, we hypothesized that the lipid content of very-low-density lipoprotein (VLDL) may have prognostic value for 1 year mortality in acute heart failure (AHF). (bvsalud.org)
Cardiovascular2
  • Low-density lipoproteins cause atherosclerotic cardiovascular disease. (nih.gov)
  • The National Heart, Lung and Blood Institute, relying on decades of data from the Framingham Heart Study, uses data on lipoprotein levels in its cardiovascular "risk assessment tool" to help guide patients who need it to treatment with lipid-lowering drugs. (unboundmedicine.com)
Levels5
  • Elevated levels of lipoproteins usually are the result of a diet too rich in fats, saturated fats, and cholesterols. (unboundmedicine.com)
  • Genetic disease also plays a part in some patients with extremely high lipoprotein levels. (unboundmedicine.com)
  • High lipoprotein levels may cause no symptoms until patients develop arterial blockages. (unboundmedicine.com)
  • Abnormal lipoprotein levels become normal in many patients who consume less dietary fat and increase their exercise. (unboundmedicine.com)
  • When lipoproteins do not reach expected levels despite diet and exercise, medications to improve lipoprotein profiles are prescribed. (unboundmedicine.com)
Develop1
Patients1
Year1
  • If you have in the paperback a personal noisy-channel to Pages on year of the word the lipoprotein is also craft it and Enter. (cdmw.de)